Acute interstitial nephritis related to immune checkpoint inhibitors
Julie Bellière(Inserm), Stanislas Faguer(Hôpital Rangueil), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), David Ribes(Centre Hospitalier Universitaire de Toulouse), S. Boulinguez(Institut universitaire du cancer de Toulouse Oncopole), Audrey Delas, Julien Mazières(Université Toulouse III - Paul Sabatier)
Cited by 103
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879